Regor Launches Phase 2 Trial for Daily GLP-1 Drug RGT-075 in Obesity

Regor Therapeutics Group, a biopharmaceutical firm with a state-of-the-art drug discovery platform, has commenced a Phase 2 clinical trial for RGT-075, an orally administered GLP-1 agonist, aimed at treating obese or overweight adults with weight-related health issues. The first patient visit took place on March 8, 2024, with the primary results anticipated to be released later in the year. According to Michael Grimm, the Chief of Metabolic Diseases at Regor, the trial's initiation is a significant step forward for RGT-075, which could offer a convenient and impactful alternative to existing weight reduction therapies. The drug is intended for daily oral use, either on its own or combined with other oral treatments for obesity. Early clinical trials have already indicated positive trends in body weight reduction.

The Phase 2 study is a multicenter, randomized, double-blind, and placebo-controlled trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of RGT-075. It will involve around 60 adults with a BMI between 27 and 45, who will be randomly assigned to receive either RGT-075 or a placebo. The treatment period is set for 12 weeks, with an initial 6-week titration phase followed by a 6-week maintenance phase at the target dosage. The study's primary data is expected to be disclosed in the latter half of 2024.

RGT-075 is a novel, once-daily, small molecule GLP-1 receptor full agonist developed by Regor for metabolic disorders, including type-2 diabetes and obesity. The drug has successfully completed Phase 1 trials, demonstrating safety and good clinical tolerability.

Established in 2018, Regor Therapeutics Group is comprised of a team of seasoned scientists with a history of success in drug discovery and development. The company's rCARD™ technology, which stands for Computer Accelerated Rational Discovery, has been instrumental in the internal completion of eight preclinical candidates and the filing of five Investigational New Drug applications, showcasing the company's efficient approach to discovering new therapeutics.

Regor's pipeline includes promising treatments in the fields of metabolism, oncology, and auto-immunity. RGT-075 is one such asset, with its potential to be a leading oral treatment for obesity. Another key asset is RGT-419B, a CDK4+ inhibitor that has shown remarkable efficacy as a single agent in treating patients with resistant ER+/HER2- breast cancer.

Regor is dedicated to excellence in pharmaceutical research and aims to establish itself as a leading innovator in the global market. The company fosters a culture of scientific excellence, strong teamwork, and shared accountability for success.